Vaccinex, Inc. (NASDAQ:VCNX) has reported new findings for its lead product, pepinemab, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference. The company has previously reported that pepinemab treatment prevents decline in glucose uptake and significantly slows cognitive decline in Huntington's disease. The new data indicates that pepinemab treatment significantly reduced blood levels of GFAP, a biomarker of reactive astrocytes, providing further evidence of the drug's potential to reverse harmful astrocyte activation and brain inflammation. The company is testing similar effects of pepinemab treatment in an ongoing trial for Alzheimer's disease.